Decoding Treatment Response in Multiple Sclerosis: The Promise of Pharmacogenomics

Multiple sclerosis (MS) is a complex immune-mediated disease of the central nervous system with marked heterogeneity in clinical course and in response to disease-modifying therapies (DMTs). Despite a growing therapeutic armamentarium, a substantial proportion of patients—often estimated at 30–50% depending on the therapy and definition of response—experience suboptimal control manifested by relapses, new radiologic activity, or progression. This clinical variability reflects complex interplay among disease biology, immune phenotypes, pharmacokinetics, and host genetics. Pharmacogenomics aims to decipher the genetic contributors to interindividual differences in both efficacy and toxicity, aspiring to inform precision therapeutic selection and timing. While candidate-gene efforts yielded early signals, systematic reviews highlight that reproducible, clinically actionable single-gene predictors across the DMT landscape remain lacking, motivating more comprehensive multi-omic and polygenic strategies. Lessons from Early Pharmacogenomic Investigations: Interferon-Beta
Interferon-beta (IFN-β), one of the first approved DMTs, has been extensively interrogated for genomic correlates of response. Initial studies explored variants in interferon signaling pathway genes (e.g., MX1/MXA), HLA alleles, and downstream gene expression signatures as potential discriminators between responders and non-responders. However, larger expression studies and systematic appraisals revealed inconsistencies and a reproducibility gap: many early candidate biomarkers failed to validate, and some proposed associations were explicitly refuted, underscoring limitations of small cohorts, heterogeneous endpoints, and population stratification in candidate-gene designs. These challenges have driven a paradigm shift toward broader, hypothesis-free approaches and integrating genetic data with dynamic immune and molecular phenotyping. Pharmacogenomic Insights Beyond Interferons: HLA and Small-Molecule Modulators
Beyond IFN-β, genetic variation in immune-related loci and drug metabolism pathways has been implicated in modulating response to other DMTs. The HLA region—central to MS susceptibility—also appears to influence therapeutic outcomes. For example, the HLA-DRB1*0403 allele has been studied for its association with failure to achieve no evidence of disease activity (NEDA) under various DMTs, with case-control data suggesting it may correlate with differential composite response, although replication and mechanistic work are ongoing. Small-molecule therapies provide a more immediately actionable pharmacogenomic exemplar: siponimod’s metabolism is substantially governed by CYP2C9 genotype. Patients with poor-metabolizer genotypes (e.g., *3/*3) are contraindicated, and dosing adjustments (such as reduced maintenance dosing for *1/*3 or *2/*3) are mandated by regulatory guidance to manage exposure and safety. These genotype-informed strategies illustrate how pharmacogenomics can already influence prescribing for select agents in MS. High-Efficacy Agents and Emerging Composite Predictors
High-efficacy therapies—particularly those targeting B cells (e.g., anti-CD20 monoclonals)—introduce additional layers of immune modulation, and differential baseline immune phenotypes may underlie variable benefit. While specific germline pharmacogenomic markers for agents like ocrelizumab remain under exploration, broader efforts are beginning to define polygenic and immunogenomic signatures for response to monoclonal antibody therapies. Similarly, a large, multicentric genome-wide association study (GWAS) of natalizumab response has identified suggestive associations implicating MS-relevant pathways including Wnt/β-catenin signaling, highlighting that response is likely governed by multi-gene networks rather than single loci. The integration of genetic data with transcriptomics, epigenetics, and cellular immune profiling is creating multidimensional “responder signatures” that could be validated prospectively in composite predictive models. Obstacles to Clinical Translation
Despite accumulating data, translating pharmacogenomic insights into routine MS care remains fraught. Many studies suffer from limited sample sizes, inconsistent response definitions, and underrepresentation of diverse ancestral backgrounds, limiting generalizability. The reproducibility problem—especially with candidate-gene findings—persists, necessitating independent validation and the adoption of rigorous, harmonized outcome measures. Moreover, the effect sizes of individual variants are generally modest, implying that clinically useful tools will require aggregation (e.g., polygenic risk scores) and incorporation of non-genetic biomarkers such as neurofilament light chain or imaging metrics. Prospectively designed trials and pragmatic real-world studies are needed to calibrate and qualify these composite predictors before broad implementation. Toward Precision Therapeutics: Opportunities and Ethical Considerations
The eventual incorporation of pharmacogenomics into MS management holds promise for optimizing drug selection, minimizing exposure to likely non-responders, and preemptively mitigating adverse events—thereby improving outcomes and resource allocation. Advances in multi-omics, machine learning for predictive modeling, and large consortia-derived datasets offer fertile ground for robust, externally validated treatment-response classifiers. However, realizing this vision demands careful attention to equity (ensuring diverse ancestral representation), transparency in conveying probabilistic genetic information to patients, data privacy protections, and adaptive updating of models as new therapies and variants emerge. Ethical frameworks should ensure personalization enhances, rather than fragments, patient-centered care. Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.

References:
Baranzini, S. E., & Oksenberg, J. R. (2017). The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. Trends in genetics : TIG, 33(12), 960–970. https://doi.org/10.1016/j.tig.2017.09.004

Coyle P. K. (2017). Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives. Multiple sclerosis international, 2017, 6198530. https://doi.org/10.1155/2017/6198530

Rommer, P. S., Milo, R., Han, M. H., Satyanarayan, S., Sellner, J., Hauer, L., Illes, Z., Warnke, C., Laurent, S., Weber, M. S., Zhang, Y., & Stuve, O. (2019). Immunological Aspects of Approved MS Therapeutics. Frontiers in immunology, 10, 1564. https://doi.org/10.3389/fimmu.2019.01564

Gomez-Gaitan, E. A., Garcia-Ortega, Y. E., Saldaña-Cruz, A. M., Contreras-Haro, B., Gamez-Nava, J. I., Perez-Guerrero, E. E., Nava-Valdivia, C. A., Gallardo-Moya, S., Martinez-Hernandez, A., Gonzalez Lopez, L., Rios-Gonzalez, B. E., Marquez-Pedroza, J., Mendez-Del Villar, M., Esparza-Guerrero, Y., Villagomez-Vega, A., & Macias Islas, M. A. (2023). Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study. International journal of molecular sciences, 24(19), 14594. https://doi.org/10.3390/ijms241914594

Faissner, S., Plemel, J.R., Gold, R. et al. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov 18, 905–922 (2019). https://doi.org/10.1038/s41573-019-0035-2